PTC Therapeutics, Inc. (NASDAQ:PTCT) was the recipient of unusually large options trading on Tuesday. Stock traders bought 27,477 put options on the stock. This is an increase of Infinity compared to the average daily volume of 0 put options.

Several large investors have recently added to or reduced their stakes in the company. California Public Employees Retirement System boosted its position in shares of PTC Therapeutics by 78.9% during the 3rd quarter. California Public Employees Retirement System now owns 34,878 shares of the biopharmaceutical company’s stock worth $698,000 after acquiring an additional 15,378 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of PTC Therapeutics by 1,587.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 400,000 shares of the biopharmaceutical company’s stock worth $8,004,000 after acquiring an additional 376,300 shares in the last quarter. Sectoral Asset Management Inc boosted its position in shares of PTC Therapeutics by 180.8% during the 3rd quarter. Sectoral Asset Management Inc now owns 170,535 shares of the biopharmaceutical company’s stock worth $3,412,000 after acquiring an additional 109,800 shares in the last quarter. RTW Investments LP boosted its position in shares of PTC Therapeutics by 5.8% during the 3rd quarter. RTW Investments LP now owns 3,495,143 shares of the biopharmaceutical company’s stock worth $69,938,000 after acquiring an additional 190,929 shares in the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of PTC Therapeutics by 8.7% during the 3rd quarter. California State Teachers Retirement System now owns 64,160 shares of the biopharmaceutical company’s stock worth $1,284,000 after acquiring an additional 5,119 shares in the last quarter. 78.53% of the stock is owned by institutional investors and hedge funds.

PTCT has been the subject of several analyst reports. ValuEngine cut PTC Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 7th. J P Morgan Chase & Co cut PTC Therapeutics from a “neutral” rating to an “underweight” rating and lowered their target price for the stock from $23.00 to $15.00 in a research note on Monday, October 9th. Zacks Investment Research cut PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Bank of America Corporation cut PTC Therapeutics from a “neutral” rating to an “underperform” rating in a research note on Thursday, October 26th. Finally, Royal Bank Of Canada set a $15.00 target price on PTC Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, October 25th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the company. PTC Therapeutics has an average rating of “Hold” and a consensus price target of $18.75.

PTC Therapeutics (NASDAQ PTCT) opened at $15.97 on Friday. PTC Therapeutics has a 1 year low of $8.12 and a 1 year high of $22.00. The company has a current ratio of 3.08, a quick ratio of 2.97 and a debt-to-equity ratio of 0.98.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/11/19/ptc-therapeutics-target-of-unusually-high-options-trading-ptct.html.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Receive News & Stock Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related stocks with our FREE daily email newsletter.